Having trouble accessing articles? Reset your cache.

Contrave: Additional Phase III data

Additional data from the double-blind, U.S. Phase III COR-I (NB-301) trial were published in the Lancet, including a sensitivity analysis of all patients who completed the full 56 weeks of

Read the full 301 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE